Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUM159PT | TNBC | Basal B | Topotecan | TOP1 | TOP | 109 | uM | 7918.007 | 0.7499 | 0.8156 | 2.9756 | |
| SUM159PT | TNBC | Basal B | Topotecan | TOP1 | TOP | 0.873 | uM | 7918.007 | 0.3147 | 0.3560 | 2.9756 | |
| SUM159PT | TNBC | Basal B | Topotecan | TOP1 | TOP | 4.37 | uM | 7918.007 | 0.0416 | -0.3131 | 2.9756 | |
| SUM159PT | TNBC | Basal B | Topotecan | TOP1 | TOP | 21.8 | uM | 7918.007 | 0.0199 | -0.4639 | 2.9756 | |
| SUM159PT | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.000221 | uM | 7918.007 | 0.7387 | 0.8065 | 2.9756 | |
| SUM159PT | TNBC | Basal B | CPT-11 | TOP1 | TOP | 0.0236 | uM | 7918.007 | 0.9946 | 0.9964 | 2.9756 | |
| SUM159PT | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 17.2 | uM | 7918.007 | 0.0432 | -0.3040 | 2.9756 | |
| SUM159PT | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 86.2 | uM | 7918.007 | 0.0042 | -0.6820 | 2.9756 | |
| SUM159PT | TNBC | Basal B | Topotecan | TOP1 | TOP | 0.175 | uM | 7918.007 | 0.1477 | 0.0517 | 2.9756 | |
| SUM159PT | TNBC | Basal B | Topotecan | TOP1 | TOP | 0.0349 | uM | 7918.007 | 0.5808 | 0.6662 | 2.9756 | |
| SUM159PT | TNBC | Basal B | CPT-11 | TOP1 | TOP | 0.118 | uM | 7918.007 | 1.1814 | 1.1152 | 2.9756 | |
| SUM159PT | TNBC | Basal B | Geldanamycin | HSP90 | HSP90 | 0.000256 | uM | 7918.012 | 0.9659 | 0.9768 | 2.9753 | |
| SUM159PT | TNBC | Basal B | Trametinib | MEK | MAPK | 16.7 | uM | 7918.012 | 0.2385 | 0.2353 | 2.9753 | |
| SUM159PT | TNBC | Basal B | Geldanamycin | HSP90 | HSP90 | 0.00128 | uM | 7918.012 | 1.0363 | 1.0241 | 2.9753 | |
| SUM159PT | TNBC | Basal B | Trametinib | MEK | MAPK | 0.0000427 | uM | 7918.012 | 0.9647 | 0.9760 | 2.9753 | |
| SUM159PT | TNBC | Basal B | Trametinib | MEK | MAPK | 3.33 | uM | 7918.012 | 0.4615 | 0.5423 | 2.9753 | |
| SUM159PT | TNBC | Basal B | Trametinib | MEK | MAPK | 0.000213 | uM | 7918.012 | 0.9900 | 0.9933 | 2.9753 | |
| SUM159PT | TNBC | Basal B | Trametinib | MEK | MAPK | 0.00107 | uM | 7918.012 | 0.8445 | 0.8896 | 2.9753 | |
| SUM159PT | TNBC | Basal B | Trametinib | MEK | MAPK | 0.00533 | uM | 7918.012 | 0.6093 | 0.6932 | 2.9753 | |
| SUM159PT | TNBC | Basal B | Trametinib | MEK | MAPK | 0.0267 | uM | 7918.012 | 0.5876 | 0.6727 | 2.9753 | |
| SUM159PT | TNBC | Basal B | Geldanamycin | HSP90 | HSP90 | 0.8 | uM | 7918.012 | 0.0516 | -0.2614 | 2.9753 | |
| SUM159PT | TNBC | Basal B | Geldanamycin | HSP90 | HSP90 | 4 | uM | 7918.012 | 0.2947 | 0.3265 | 2.9753 | |
| SUM159PT | TNBC | Basal B | Geldanamycin | HSP90 | HSP90 | 20 | uM | 7918.012 | 0.2259 | 0.2130 | 2.9753 | |
| SUM159PT | TNBC | Basal B | Geldanamycin | HSP90 | HSP90 | 100 | uM | 7918.012 | 0.0524 | -0.2575 | 2.9753 | |
| SUM159PT | TNBC | Basal B | Trametinib | MEK | MAPK | 0.133 | uM | 7918.012 | 0.3763 | 0.4400 | 2.9753 |